Illinois Tool Works Inc. vs Oruka Therapeutics Inc. Common Stock — how do they compare? Illinois Tool Works Inc. trades at $269.47 (market cap $75.85B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Illinois Tool Works Inc. is far larger — about 14.6× Oruka Therapeutics Inc. Common Stock's market cap, and Illinois Tool Works Inc. pays a 2.58% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 66 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| ITW | ORKA | |
|---|---|---|
Market Cap | $75.85B | $5.18B |
Volume | 960,368 | 490,798 |
Sector | Industrials | Health |
52-Week High | $299.60 | $113.08 |
52-Week Low | $241.07 | $26.19 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $84.70B | $4.31B |
Dividend Yield | 2.58% | — |
Signals from Pluang's Aura AI — not financial advice
ITW trades at $269.47, up 1.64% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 19.39% net margins and 104.65% ROE. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of growth. Revenue stability around $16B and operational cash flow exceeding $3B demonstrate business resilience despite mixed analyst sentiment.
Outlook remains balanced with upside to $276.86 consensus target but faces headwinds from elevated P/E of 24.12 and bearish technical momentum. The company's disciplined capital allocation and sector diversification provide stability, though automotive and foodservice weaknesses present near-term challenges. Valuation appears full given current growth rates.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →